Related Experiment Video
Updated: May 14, 2026
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening
Yongmei Pan1, Paresh P Chothe, Peter W Swaan
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, 20 Penn Street, Baltimore, Maryland 21201, USA.
Abstract:
Breast cancer resistance protein (BCRP; ABCG2) is an efflux transporter that plays an important role in multidrug resistance to antineoplastic drugs. The identification of drugs as BCRP inhibitors could aid in designing better therapeutic strategies for cancer treatment and will be critical for identifying potential drug-drug interactions. In the present study, we applied ligand-based virtual screening combined with experimental testing for the identification of novel drugs that can possibly interact with BCRP. Bayesian and pharmacophore models generated with known BCRP inhibitors were validated with an external test set. The resulting models were applied to predict new potential drug candidates from a database with more than 2000 FDA-approved drugs. Thirty-three drugs were tested in vitro for their inhibitory effects on BCRP-mediated transport of [(3)H]-mitoxantrone in MCF-7/AdrVp cells. Nineteen drugs were identified with significant inhibitory effect on BCRP transport function. The combined strategy of computational and experimental approaches in this paper has suggested potential drug candidates and thus represents an effective tool for rational identification of modulators of other proteins.
Insights
Researchers identified 19 FDA-approved drugs that inhibit breast cancer resistance protein (BCRP), a key factor in multidrug resistance. This discovery aids in developing new cancer therapies and predicting drug interactions.
Area of Science:
- Pharmacology
- Biochemistry
- Computational Chemistry
Background:
- Breast cancer resistance protein (BCRP; ABCG2) is an efflux transporter implicated in multidrug resistance to antineoplastic drugs.
- Identifying BCRP inhibitors is crucial for improving cancer treatment strategies and predicting drug-drug interactions.
Purpose of the Study:
- To identify novel drugs that interact with BCRP using a combined computational and experimental approach.
- To validate predictive models for BCRP modulators.
Main Methods:
- Ligand-based virtual screening using validated Bayesian and pharmacophore models.
- In vitro testing of FDA-approved drugs for BCRP inhibitory effects on mitoxantrone transport in MCF-7/AdrVp cells.
Main Results:
- Nineteen out of thirty-three tested FDA-approved drugs demonstrated significant inhibition of BCRP-mediated transport.
- The study successfully identified novel BCRP inhibitors from a large drug database.
Conclusions:
- The combined computational and experimental strategy is effective for identifying BCRP modulators.
- The identified drugs represent potential candidates for enhancing cancer therapy and managing drug interactions.
